Loading organizations...
§ Private Profile · Austin, TX, USA
Clinical-stage protein engineering company developing selective TGF-beta 1 and 3 inhibitors for cancer and fibrotic diseases.
Forbius is an Austin, Texas-based clinical-stage protein engineering company that develops selective TGF-beta inhibitors for the treatment of cancer and fibrotic diseases. The organization focuses on targeting TGF-beta 1 and 3 isoforms to enhance anti-tumor efficacy, advancing its lead asset, AVID200, through Phase 1a clinical trials for solid tumors. Operating with 10 to 50 employees, the company secured multiple venture capital rounds, including a 2014 financing and a 2017 Series B backed by Lumira Capital, HBM Healthcare Investments, and Toronto Innovation Acceleration Partners. In August 2020, Bristol Myers Squibb acquired the company's TGF-beta program for an undisclosed upfront payment and future milestones, spinning out remaining assets into a separate private entity. Originally spun out from YM BioSciences as AvidBiologics, Forbius was founded in 2011 and led by President and Chief Executive Officer Ilia A. Tikhomirov.
Forbius has raised $18.8M across 1 funding round.
Forbius has raised $18.8M in total across 1 funding round.
Forbius has raised $18.8M in total across 1 funding round.
Forbius's investors include Cancer Prevention and Research Institute of Texas.
Forbius has raised $18.8M across 1 funding round. Most recently, it raised $18.8M Grant in August 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 24, 2018 | $18.8M Grant | Cancer Prevention And Research Institute OF Texas | — | Announced |